Sökning: WFRF:(Öhrfelt Annika 1973 ) > (2015-2019) > (2017) > Öhrfelt Olsson Annika 1973 > Mass Spectrometric ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05591naa a2200493 4500 | |
001 | oai:lup.lub.lu.se:8bc5e65e-4b1b-4dba-bf09-bda69151ffc8 | |
003 | SwePub | |
008 | 180103s2017 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/260521 | |
024 | 7 | a https://lup.lub.lu.se/record/8bc5e65e-4b1b-4dba-bf09-bda69151ffc82 URI |
024 | 7 | a https://doi.org/10.1002/prca.2017001002 DOI |
024 | 7 | a https://gup.ub.gu.se/publication/2605212 URI |
040 | a (SwePub)lud (SwePub)gu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Sjödin, Simonu Gothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xsjsim |
245 | 1 0 | a Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders |
264 | c 2017-11-02 | |
264 | 1 | b Wiley,c 2017 |
520 | a Purpose: Dysfunctional proteostasis, with decreased protein degradation and an accumulation of ubiquitin into aggregated protein inclusions, is a feature of neurodegenerative diseases. Identifying new potential biomarkers in cerebrospinal fluid (CSF) reflecting this process could contribute important information on pathophysiology. Experimental design: A developed method combining SPE and PRM-MS is employed to monitor the concentration of ubiquitin in CSF from subjects with Alzheimer's disease (AD), Parkinson's disease (PD), and progressive supranuclear palsy (PSP). Four independent cross-sectional studies are conducted, studies 1–4, including controls (n = 86) and participants with AD (n = 60), PD (n = 15), and PSP (n = 11). Results: The method shows a repeatability and intermediate precision not exceeding 6.1 and 7.9%, respectively. The determined LOD is 0.1 nm and the LOQ range between 0.625 and 80 nm. The CSF ubiquitin concentration is 1.2–1.5-fold higher in AD patients compared with controls in the three independent AD-control studies (Study 1, p < 0.001; Study 2, p < 0.001; and Study 3, p = 0.003). In the fourth study, there is no difference in PD or PSP, compared to controls. Conclusion and clinical relevance: CSF ubiquitin may reflect dysfunctional proteostasis in AD. The described method can be used for further exploration of ubiquitin as a potential biomarker in neurodegenerative diseases. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
653 | a alzheimer's disease | |
653 | a biomarker | |
653 | a parkinson's disease | |
653 | a progressive supranuclear palsy | |
653 | a ubiquitin | |
700 | 1 | a Hansson, Oskaru Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)mphy-ohn |
700 | 1 | a Öhrfelt Olsson, Annika,d 1973u Gothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xohrfa |
700 | 1 | a Brinkmalm, Gunnaru Gothenburg University,Göteborgs universitet,University of Gothenburg,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbrigu |
700 | 1 | a Zetterberg, Henriku Gothenburg University,Göteborgs universitet,University of Gothenburg,University College London,Sahlgrenska University Hospital,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe |
700 | 1 | a Brinkmalm-Westman, Ann,d 1966u Gothenburg University,Göteborgs universitet,University of Gothenburg,Sahlgrenska University Hospital,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbrian |
700 | 1 | a Blennow, Kaju Gothenburg University,Göteborgs universitet,University of Gothenburg,Sahlgrenska University Hospital,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka |
710 | 2 | a University of Gothenburgb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Proteomics - Clinical Applicationsd : Wileyg 11:11-12q 11:11-12x 1862-8346x 1862-8354 |
856 | 4 | u http://dx.doi.org/10.1002/prca.201700100x freey FULLTEXT |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prca.201700100 |
856 | 4 8 | u https://lup.lub.lu.se/record/8bc5e65e-4b1b-4dba-bf09-bda69151ffc8 |
856 | 4 8 | u https://doi.org/10.1002/prca.201700100 |
856 | 4 8 | u https://gup.ub.gu.se/publication/260521 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy